Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Ulcerative Colitis
Interventions
DRUG

AVX 470

active comparator

DRUG

Placebo

Trial Locations (16)

1083

Semmelweis Egyetem, Budapest

3000

Gastro-enterologie, Leuven

4032

Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen

4043

Kenézy Kórház Rendelöintézet Egészségügyi Szolgáltató Kft., Debrecen

9000

Gastro-Enterologie, Ghent

20815

Chevy Chase Clinical Research, Chevy Chase

37205

Nashville Medical Research Institute, Nashville

43215

Remington-Davis, Inc., Columbus

48047

Clinical Research Institute of Michigan, Chesterfield

65265

Center for Digestive and Liver Disease, Mexico

73104

Oklahoma Foundation for Digestive Research, Oklahoma City

80215

Rocky Mountain Gastroenterology Associates, Lakewood

92801

Anaheim Clinical Trials, Anaheim

327789

Shafran Gastroenterology Center, Winter Park

T6G 2C8

The Northern Alberta Clinical Trials and Research Centre, Edmonton

L4L 4Y7

Toronto Digestive Disease Associates, Toronto

All Listed Sponsors
lead

Avaxia Biologics, Incorporated

INDUSTRY

NCT01759056 - Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter